Payment overview · 2025
General Payments
$2,298.18
116 reported records · 21 companies
Healthcare provider profile · identity verified
Donald David Dangle, DO
Allopathic & Osteopathic Physicians|Family Medicine · LOYSVILLE, PA · NPI 1003171141
Verified facts
What the public records show
CMS Open Payments records show Donald David Dangle, DO received $2,298.18 in general payments during 2025 across 116 reported records.
ABBVIE INC. accounted for 18.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 295 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 295 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $420.71 | 18.3% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $413.40 | 18.0% | 24 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $227.55 | 9.9% | 7 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $168.00 | 7.3% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $162.94 | 7.1% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $158.04 | 6.9% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $147.83 | 6.4% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $145.75 | 6.3% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $72.42 | 3.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.15 | 3.1% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.82 | 2.6% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.68 | 2.4% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $31.04 | 1.4% | 2 | 2025 |
| Sonex Health, Inc. | Unresolved — no canonical attribution shown | $26.56 | 1.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.08 | 1.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.36 | 1.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.86 | 0.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.24 | 0.8% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.67 | 0.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.85 | 0.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.23 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,298.18 | 116 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $237.59 | 14 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $237.59 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $210.99 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $198.22 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $194.67 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $194.26 | 10 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $168.00 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $162.94 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $158.04 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $148.63 | 9 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $147.34 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $146.37 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $108.52 | 6 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $108.52 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $80.33 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $72.42 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.15 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $65.42 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $58.82 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $53.69 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.31 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $39.31 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.31 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $35.05 | 2 | 2025 |
Source payment records
|
|||||
| SX-ONE MICROKNIFE Normalized: sx one microknife |
Device | Sonex Health, Inc. | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.57 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 122 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 295 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 161 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 118 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
295 | 57 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
118 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
295 | 57 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
161 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
122 | 24 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 655 | 161 |
| Lisinopril | Lisinopril | 651 | 149 |
| Montelukast Sodium | Montelukast Sodium | 482 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 397 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 89 |
| Gabapentin | Gabapentin | 372 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 372 | 96 |
| Jardiance | Empagliflozin | 295 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 294 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 287 | 47 |
| Prednisone | Prednisone | 256 | 177 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 71 |
| Furosemide | Furosemide | 241 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 236 | 88 |
| Famotidine | Famotidine | 222 | 52 |
| Losartan Potassium | Losartan Potassium | 211 | 52 |
| Omeprazole | Omeprazole | 199 | 49 |
| Ezetimibe | Ezetimibe | 191 | 41 |
| Buspirone Hcl | Buspirone Hcl | 184 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 183 | 38 |
| Tradjenta | Linagliptin | 169 | 26 |
| Sertraline Hcl | Sertraline Hcl | 165 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 164 | 60 |
| Ozempic | Semaglutide | 161 | 31 |
| Meloxicam | Meloxicam | 155 | 41 |
| Potassium Chloride | Potassium Chloride | 154 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 148 | 35 |
| Alendronate Sodium | Alendronate Sodium | 145 | 30 |
| Metformin Hcl | Metformin Hcl | 141 | 37 |
| Trazodone Hcl | Trazodone Hcl | 140 | 26 |
| Glipizide Er | Glipizide | 133 | 23 |
| Eliquis | Apixaban | 122 | 24 |
| Lorazepam | Lorazepam | 121 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 25 |
| Carvedilol | Carvedilol | 118 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 118 | 19 |
| Baclofen | Baclofen | 114 | 29 |
| Topiramate | Topiramate | 113 | 22 |
| Myrbetriq | Mirabegron | 112 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 27 |
| Pregabalin | Pregabalin | 105 | 25 |
| Tramadol Hcl | Tramadol Hcl | 105 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 102 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 19 |
| Simvastatin | Simvastatin | 89 | 26 |
| Donepezil Hcl | Donepezil Hcl | 88 | 15 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 84 | 16 |
| Allopurinol | Allopurinol | 76 | 17 |
| Clonazepam | Clonazepam | 75 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 19 |
| Cefuroxime | Cefuroxime Axetil | 70 | 66 |
| Celecoxib | Celecoxib | 68 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 61 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 24 |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Atenolol | Atenolol | 58 | 12 |
| Bumetanide | Bumetanide | 57 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 30 |
| Roflumilast | Roflumilast | 56 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 55 | 11 |
| Synthroid | Levothyroxine Sodium | 54 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 51 | suppressed |
| Invokana | Canagliflozin | 51 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Azithromycin | Azithromycin | 48 | 36 |
| Bupropion Xl | Bupropion Hcl | 47 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 11 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Fenofibrate | Fenofibrate | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 12 |
| Memantine Hcl | Memantine Hcl | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 34 |
| Finasteride | Finasteride | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 19 |
| Ondansetron Odt | Ondansetron | 31 | 21 |
| Rybelsus | Semaglutide | 31 | suppressed |
| Valsartan | Valsartan | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Nystatin | Nystatin | 26 | 22 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 25 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 15 |
| Fentanyl | Fentanyl | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Metaxalone | Metaxalone | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 14 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 11 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,298.18 · 116 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, COMIRNATY, CONTRAVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, SHINGRIX, SX-ONE MICROKNIFE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error